FILE:LIFE/LIFE-8K-20040217121501.txt.gz
EVENTS:	Other events	Financial statements and exhibits
TEXT:
ITEM: Other events
ITEM: Financial statements and exhibits
 
 
 
 
 
 
 
 
 
 
 
 
 
On February 12, 2004, Invitrogen Corporation (the "Company") issued two press releases regarding its offering of $450 million aggregate principal amount of 1.5% Convertible Senior Notes due 2024 plus a 13 day over-allotment option to purchase up to an additional $67.5 million of 1.5% Convertible Senior Notes to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Attached as Exhibits 99.1 and 99.2 are press releases of the Company regarding the offering of the Convertible Senior Notes. Exhibits 99.1 and 99.2 are incorporated by reference under this Item 5.
 
 
(c) Exhibits.
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 

Exhibit 99.1
 
Investor and Financial Contacts:
 
Eric Winzer
(760) 603-7200
 
 
Invitrogen Corporation (Nasdaq: IVGN) announced today that it plans to offer $450 million of senior convertible notes due 2024 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Company also plans to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $67.5 million aggregate principal amount of the notes.
CARLSBAD, CA, February 12, 2004
 
Invitrogen plans to use a portion of the net proceeds from the sale of the notes to redeem its 5% Convertible Subordinated Notes due 2007 in the aggregate principal amount of $172.5 million. The remaining balance of the net proceeds will be used for potential acquisitions and general corporate purposes, including the potential repayment of other outstanding debt.
 
This announcement is neither an offer to sell nor a solicitation to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The securities will not be registered under the Securities Act, or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws.
 
 

Exhibit 99.2
 
Investor and Financial Contacts:
 
Eric Winzer
(760) 603-7200
 
 
Invitrogen Corporation (Nasdaq: IVGN) announced today the pricing of $450 million of 1% senior convertible notes due 2024 sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Company has also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $67.5 million aggregate principal amount of the notes. The sale of the notes is expected to close on February 19, 2004.
CARLSBAD, CA, February 12, 2004
 
Under certain circumstances the notes will be convertible into the Company's common stock at a conversion rate of 9.8015 shares per $1,000 principal amount of the notes, subject to adjustment (equal to an initial conversion price of approximately $102.03 per share). The closing sale price for the Company's common stock on February 12, 2004 was $77.00 per share.
 
In addition, beginning with the six month period commencing on February 15, 2012, the Company will pay contingent interest on the notes during a six-month interest period if the average trading price of the notes is above a specified level.
 
The Company intends to use a portion of the net proceeds to redeem its 5% Convertible Subordinated Notes due 2007 in the aggregate principal amount of $172.5 million. It intends to use the balance of the net proceeds for potential acquisitions and for general corporate purposes, including the potential repayment or redemption of other outstanding debt.
 
This announcement is neither an offer to sell nor a solicitation to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. The securities will not be registered under the Securities Act, or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws.


